Year: 2024
Type: article
Abstract: Conclusions: Our transcriptomic results suggest that induction of anti-cancer immunity is possible in anti-PD-(L)1-refractory mUC, but in this setting a degree of preexisting immune activity might be necessary but not sufficient to mount a durable immune response upon anti-CTLA-4 treatment.Clinical trial identification: NCT03871036.
Source: Immuno-Oncology Technology
Authors: M. Presti, I. Lobon, M. Sánchez Sánchez, S. Khan, S. Turajlic, M. Donia
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
Funders: Novo Nordisk, H. Lundbeck A/S
OpenAlex ID: W4405373974